Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.

CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.

Search Results

1277 Results

34 – Clinical Management of Women With HIV in Menopause

Menopause represents a highly vulnerable time for women physically, mentally, and socially. The growing body of menopause research among women living with HIV (WLWH) demonstrates that this vulnerable population experiences greater mood and vasomotor symptom burden, which adversely impacts adherence to clinic visits and antiretroviral therapy. Estrogen loss associated with menopause may further enhance the…

22 – HIV Care Continuum in Children

Children aged 0-15 years lag behind adults in achieving HIV treatment goals across HIV testing, initiation of antiretroviral therapy and viral suppression. While early diagnosis of pediatric HIV has scaled up significantly, children continue to slip through the cracks and remain undiagnosed and untreated. For children living with HIV, challenges in adherence to treatment is…

51 – We’ll Come to You: A Mobile Clinic Preexposure Prophylaxis Delivery Model

Effective HIV prevention requires well-designed and well-targeted services tailored according to client characteristics and needs. PrEP biomedical product choice allows young people to select a formulation that works for them and their lifestyle, while HIV prevention impact may be even greater if PrEP service delivery models also match young people’s diverse lifestyles and unique needs.…

19 – Cellular and Tissue Sources of Viral Persistence and Rebound

Cellular and tissue sources of viral rebound primarily originate from long-lived reservoirs of HIV in individuals under antiretroviral therapy (ART). Key cellular reservoirs include CD4+ T cells, particularly memory subsets like central memory (Tcm), which harbor latent provirus. Tissue-specific sources include lymphoid tissues (lymph nodes, spleen, and gut-associated lymphoid tissue), where virus can persist despite…

38 – Game Changed: Navigating the Era of Long-Acting Therapies for HIV Prevention

We are at the dawn of a new era of long-acting antiretroviral (ARV) agents that promises to revolutionize the prevention of HIV infection. The HPTN083 and 084 studies first demonstrated the promise of cabotegravir for HIV pre-exposure prophylaxis (PrEP), but its use needs to be balanced with frequent injections, risks of drug resistance and challenges…

47 – Dolutegravir Resistance: What Are the Implications for Antiretroviral Therapy Programs?

Introduction DTG-based regimens have simplified management for providers: Resistance to 1st-line DTG-based regimens is still incredibly rare. Therefore limited role for resistance testing in this scenario; can mostly assume non-adherence if viral load elevated. Fewer resistance tests required; less unnecessary switching drug classes, esp. in LMIC.  “Blind” switching to DTG-based regimens without requiring a resistance…

15 – N’Galy-Mann Lecture: When Science Alone is Not Enough: The Intersection of Drug Use, Public Health, and Policy

From the beginning of the pandemic, people who inject drugs (PWID) were identified as a key population at significant risk of HIV infection. However, despite evidence of the effectiveness of harm reduction, many countries failed to respond adequately or in a timely manner. Embedded in prohibition and punitive approaches, Malaysia’s initial resistance to harm reduction…

45 – Emerging Role of T Cells in the Central Nervous System

This presentation will address how T cell and specific T cell subsets are revealing new insights in neuroHIV pathogenesis, specifically in HIV neuroinvasion, persistence, and neuroprotection. Recent data will show the establishment and maintenance of infected CD4 T cells in the brain from acute infection to ART-suppression, discuss the role of CD8 T cells in…

28 – Systems Vaccinology

Although the development of effective vaccines has saved countless lives from infectious diseases, the basic workings of the human immune system are complex and have required the development of animal models, such as inbred mice, to define mechanisms of immunity. However, past results are not necessarily a reliable guide to the future, and a notable…

30 – How HIV Integrates Into the Genome

The HIV Preintegration Complex (PIC) mediates the integration of the viral reverse transcript into host cell chromosomes. The HIV core is composed of a shell of capsid protein that encases the viral RNA together with reverse transcriptase and integrase enzymes. Reverse transcription occurs within the viral core, and nicking of the viral DNA ends by…